AUTHORS
Swee Lay Thein, MD, DSc, Kang Le, PhD2, Jennifer Nwokeji3, Shruti Bhatt, PhD4, Shijinqiu Gao, MSc5, Anna Conrey6
AFFILIATIONS
1 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
2 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
3 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
4 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
5 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
6 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
ABSTRACT
Sickle cell disease (SCD) affects an estimated 8 million people globally, including 100,000 in the US, with substantial morbidity and early mortality, Recurrent vaso-occlusive crises (VOCs) and episodes of acute pain, are the leading cause of SCD-related hospitalizations. VOCs are triggered by red blood cell (RBC) sickling and accompanied by acute-on-chronic hemolysis from a weakened RBC membrane, releasing damage-associated molecular patterns (DAMPs), inflammatory cytokines, and proadhesive factors that promote hypoxia and further sickling, a self-amplifying cycle that can rapidly escalate a prodrome into a full crisis. Most painful episodes lack an identifiable trigger, though patients often experience this prodromal phase. Current VOC management focuses on symptomatic relief once a crisis is established, leaving a critical gap in disease-modifying options that act during this early, potentially reversible window.
Extracellular vesicles (EVs) and free heme released upon membrane compromise are key drivers of VOC pathophysiology, making membrane restoration a mechanically justified target. Phosphorylation of band 3 tyrosine residues (Tyr8, Tyr21) weakens lipid bilayer-cytoskeleton attachment by disassociating ankyrin from band 3, causing blebbing, vesiculation and heme release. We previously showed that mitapivat, a pyruvate kinase activator, reduces tyrosine-phosphorylated band 3 (Tyr-p-bd3) by increasing intracellular ATP, improving membrane integrity and RBC lifespan, with reductions in Tyr-p-bd3 detectable ex vivo within 4 hours, raising the possibility of intervening before a prodrome progresses to crisis. Here we examine early biomarker changes in a dose-ascending mitapivat study and its potential for pre-emptive VOC intervention.
We analyzed frozen whole blood/plasma from the Phase 1 mitapivat Dose-Ascending Study (NCT04000165). Of 16 enrolled patients, evaluable samples from 12 were used to isolate RBC membranes at predose, 1, 2, 4, 8, and 12 hours post-dose (5 mg, 20 mg, 50 mg, and 100 mg); heme was measured in parallel (12-hour timepoints available for 4 of the 12 patients). Mean percentage change in Tyr-p-bd3 and heme from predose were calculated at timepoint/dose and tested against a null of 0% (two-sided one-sample t-tests). Separately, 9 paired frozen whole blood/plasma samples from HbSS patients in steady vs. crisis state (Acute Pain Study, NCT03049475) were analyzed for Tyr-p-bd3 (western blot) and heme. Crisis-to-steady-state ratios (null = 1) were tested using two-sided one-sample t-tests; Spearman correlation assessed association between percentage changes in each marker from steady state. Statistical significance was set at p<0.05. Ex vivo, HbSS RBCs were pretreated with mitapivat for 2 hours before hypoxia exposure, with supernatants collected at baseline, 2, 4, 8, and 10 hours post-hypoxia. EV concentration and heme were measured by nanoparticle tracking analysis and the QuantiChrom Heme Assay, respectively (mitapivat at 50 uM, 100 uM).
As of submission, Tyr-p-bd3 and plasma heme analyses were complete for 5 and 12 patients, respectively, in the Phase 1 Dose-Ascending Study. Mitapivat reduced mean Tyr-p-bd3 within 8 hours at all doses (within 4 hours at ≥20 mg) and reduced mean heme within 8 hours at all doses, with dose-and time-dependent effects for both markers. Tyr-p-bd3 and plasma heme were significantly higher during crisis than steady-state (p< 0.01 and p< 0.05, respectively), and percentage changes in the 2 markers at steady-state were positively correlated (Spearman rank correlation: ρ = 0.70, two-sided p = 0.0358; n = 9). Ex vivo, hypoxia dramatically increased EV and heme release over time, while mitapivat pretreatment largely blocked this release, with effects apparent by 2 hours post-hypoxia.
Compromised RBC membrane integrity and erythroid DAMP release represent the step most temporally proximal to the prodrome-to-crisis transition, making restoration of membrane integrity a mechanistically plausible strategy to interrupt triggering events during this window. Mitapivat rapidly improved membrane integrity both ex vivo and in vivo, with biomarker changes emerging within hours of dosing, a timescale that aligns with the brief prodromal period preceding most VOCs. These findings position mitapivat as a candidate for pre-emptive, disease-modifying intervention within this narrow but clinically actionable therapeutic window, rather than for symptomatic relief after a crisis has begun.
DISCLOSURES
Kang Le, PhD: No relevant conflicts of interest to declare.